Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women

Assiut University66 enrolled

Overview

Iron deficiency is the most prevalent nutritional deficiency and the most common cause of anemia .It is characterized by a defect in hemoglobin synthesis, resulting in red blood cells that are abnormally small (microcytic) and contain a decreased amount of hemoglobin (hypochromic).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Anemia

Interventions

Iron dextranDRUG

total dose infusion

Ferrous FumarateDRUG

oral tablets

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hemoglobin \< 10 g/dL * Gestational age between 14-28 weeks. * Willingness to participate and signing the informed consent form. Exclusion Criteria: * Iron overload or disturbances in utilization of iron * Decompensated liver cirrhosis and active hepatitis * Active acute or chronic infections * History of multiple allergies * Known hypersensitivity to parenteral iron or any recipients in the investigation drug products * Erythropoietin treatment within 8 weeks prior to the screening visit * Other iron treatment or blood transfusion within 4 weeks prior to the screening visit * Planned elective surgery during the study.

Locations (1)

Assiut Faculty of Medicine

Asyut, Egypt

Outcomes

Primary Outcomes

The change in Hemoglobin concentration from baseline to 8 weeks therapy

measure hemoglobin level before and after treatment

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.